



Revance Therapeutics
 Investor Relations Department
 7555 Gateway Boulevard
 Newark, CA 94560
 United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: RVNC	
Last Trade:	26.20
Trade Time:	10:46 AM ET Oct 18, 2017
Change:	0.10 (+0.383%)
Day Range	25.75 - 26.30
52-Week Range	12.35 - 28.75
Volume	23,948


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Revance, a Silicon Valley-based biotechnology company, is committed to the advancement of remarkable science. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS® peptide technology, which, when combined with active drug molecules, may help address current unmet needs.

Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthe... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Oct 18, 2017*
[Revance Completes Patient Enrollment in Phase 2 Program for RT002 Injectable in the Management of Plantar Fasciitis](#)
- Sep 19, 2017*
[Revance to Participate in the Cantor Fitzgerald 2017 Global Healthcare Conference](#)
- Sep 6, 2017*
[Revance Appoints Mark Foley to its Board of Directors](#)
- Aug 30, 2017*
[Revance to Participate in the 2017 Wells Fargo Securities Healthcare Conference](#)
- Aug 3, 2017*
[Revance Releases Second Quarter 2017 Results](#)

Financials [\[View all \]](#)

- [Second Quarter Financial Results](#)
- Feb 28, 2017*
[Annual Report \(10-K\)](#)
- Mar 24, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Aug 4, 2017*
[Quarterly Report \(10-Q\)](#)
- May 9, 2017*
[Quarterly Report \(10-Q\)](#)
- Nov 4, 2016*
[Quarterly Report \(10-Q\)](#)